China's Ruiyi Xulian raises ~$15M for brain-spine implant push
What's the deal? Suzhou Ruiyi Xulian Medical Technology has raised a Pre-Series A round of US$13.8M, it announced in November. Puhua CapitalDealroom has a profile for this one. Try Dealroom → and Furong Investment co-led, with Sunny Capital and Beigong Investment joining.
What's the endgame? Founded in 2024, the company develops implantable, two-way brain-computer interfaces and neuromodulation systems. It builds its implants from interchangeable modules — sensors, read and write units, power and AI compute — aiming for "one platform, multiple scenarios."
Where the money goes: The funds will push its core brain-spine interface (BSI) product into clinical trials and support mass production of the modular platform. The company also plans to extend into language decoding, vision restoration, and depression.
Why now? Ruiyi Xulian reported early clinical results in spinal cord injury and stroke. It moved into a 5,000m² Suzhou production base in July 2026 and says it has already run a full commercial loop — development, registration, production, and sales — through earlier approved devices.
What could go wrong? The core implant is still early. The company plans to begin registration trials for the BSI in 2027 and targets a Class III medical device approval by late 2029 — a long road. Newer targets like vision and depression remain in research, not proven markets.
The signal: Chinese brain-computer interface funding is shifting from proof-of-concept toward clinical and industrial scale-up. This is Ruiyi Xulian's second near-100-million-CNY raise in 2026, following a Pre-A round in May — but it still trails leaders like NeuroXess, which closed a 700-million-CNY Series B in October.
Read more: sohu.com
Image credit: Generated with Gemini